Assist. Prof. Leyla Baykal Selcuk, MD, Karadeniz Techinical University School of Medicine, Department of Dermatology and Venerology, Trabzon, Turkey;
Acta Dermatovenerol Croat. 2022 Dec;30(4):209-215.
COVID-19 infection can have a poor prognosis, especially in patients with chronic diseases and those receiving immunosuppressive or immunomodulating therapies. This study aimed to investigate the severity of COVID-19 infection in patients with psoriasis and compare the infection severity for systemic treatments and comorbidities. We conducted a study in the dermatology clinics of five different centers in the Eastern Black Sea region of Turkey. Four hundred and eighty-eight patients were included, and 22.5% were confirmed as having COVID-19 infection. In our study, the frequency of hospitalization rates due to COVID-19 infection were similar (15.4%, 25.9% respectively) in patients receiving biological treatment and receiving non-biological systemic treatment (P=0.344). Hospitalization rates were higher in patients with hypertension, androgenetic alopecia, and acitretin use (P=0.043, P=0.028, P=0.040). In conclusion, current biologic treatments and non-biologic systemic treatments in patients with psoriasis did not appear to increase the risk of the severe form of COVID-19, except for acitretin.
COVID-19 感染可能预后不良，特别是在患有慢性病和接受免疫抑制或免疫调节治疗的患者中。本研究旨在调查银屑病患者 COVID-19 感染的严重程度，并比较全身治疗和合并症的感染严重程度。我们在土耳其黑海东部五个不同中心的皮肤科诊所进行了一项研究。共纳入 488 例患者，其中 22.5% 确诊为 COVID-19 感染。在我们的研究中，因 COVID-19 感染而住院的频率在接受生物治疗和接受非生物全身治疗的患者中相似（分别为 15.4%和 25.9%，P=0.344）。患有高血压、雄激素性脱发和阿维 A 治疗的患者住院率更高（P=0.043、P=0.028、P=0.040）。总之，除了阿维 A 外，目前银屑病患者的生物治疗和非生物全身治疗似乎并未增加 COVID-19 严重形式的风险。
